Implications of Coronary Artery Calcium Testing Among Statin Candidates According to American College of Cardiology/American Heart Association Cholesterol Management Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis) (vol 66, pg 1657, 2015)
Year: 2015
Type: article
Abstract: BACKGROUND The American College of Cardiology (ACC)/American Heart Association (AHA) cholesterol management guidelines have significantly broadened the scope of candidates eligible for statin therapy.OBJECTIVES This study evaluated the implications of the absence of coronary artery calcium (CAC) in reclassifying patients from a risk stratum in which statins are recommended to one in which they are not. METHODS MESA (Multi-Ethnic Study of Atherosclerosis) is a longitudinal study of 6,814 men and women 45 to 84 years of age without clinical atherosclerotic cardiovascular disease (ASCVD) risk at enrollment.We excluded 1,100 participants (16%) on lipid-lowering medication, 87 (1.3%) without low-density lipoprotein levels, 26 (0.4%) with missing risk factors for calculation of 10-year risk of ASCVD, 633 (9%) >75 years of age, and 209 (3%) with low-density lipoprotein <70 mg/dl from the analysis. RESULTSThe study population consisted of 4,758 participants (age 59 Æ 9 years; 47% males).A total of 247 (5.2%) ASCVD and 155 (3.3%) hard coronary heart disease events occurred over a median (interquartile range) follow-up of 10.3 (9.7 to 10.8) years.The new ACC/AHA guidelines recommended 2,377 (50%) MESA participants for moderate-to highintensity statins; the majority (77%) was eligible because of a 10-year estimated ASCVD risk $7.5%.Of those recommended statins, 41% had CAC ¼ 0 and had 5.2 ASCVD events/1,000 person-years.Among 589 participants (12%) considered for moderate-intensity statin, 338 (57%) had a CAC ¼ 0, with an ASCVD event rate of 1.5 per 1,000 personyears.Of participants eligible (recommended or considered) for statins, 44% (1,316 of 2,966) had CAC ¼ 0 at baseline and an observed 10-year ASCVD event rate of 4.2 per 1,000 person-years.CONCLUSIONS Significant ASCVD risk heterogeneity exists among those eligible for statins according to the new guidelines.The absence of CAC reclassifies approximately one-half of candidates as not eligible for statin therapy.
Authors: Nasir, K, Bittencourt, MS, Blaha, MJ, Blankstein, R, Agatson, AS, Rivera, JJ, Miedema, MD, Sibley, CT, Shaw, LJ, Blumenthal, RS, Budoff, MJ, Krumholz, HM
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7001115413